• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Compounds of Formula I are novel and useful as cardiovascular agents, particularly anti-arrhythmic agents: or the 5-amino tautomerthereof or a salt of either, wherein R1 is C1-10alkyl, C2-loalkenyl, C2-loalkynyl or C3-iocycloalkyl, any of which is optionally substituted, and R2 to R6 are independently selected from hydrogen, halogen atom, C1-6alkyl, alkenyl or alkynyl (all optionally substituted by one or more of halogen, hydroxy and aryl), amino, mono- or di-substituted amino, alkoxy (optionally substituted by one or more of halogen, hydroxy and aryl), alkenyloxy, acyl, acyloxy, cyano, nitro, aryl and alkylthio groups or any adjacent two of R2 to R6 are linked to form a (-CH=CH-CH=CH-) group.
    公开号:SU1371500A3
    申请号:SU843805251
    申请日:1984-10-26
    公开日:1988-01-30
    发明作者:Аллан Джеффри；Айнсли Миллер Алистэйр；Алан Сойер Давид
    申请人:Дзе Веллкам Фаундейшн Лимитед (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to a method for producing new triazine derivatives of a common formula.
    s
    R
    -N-r,
    t /
    where R, - With, -C-alkyl, unsubstituted
    or substituted by phenyl, independently two or three
    halo group, or any of the means C-C4-alkyl or C, -C-alkoxy group, and in any case, the rest of Rj is Rg-hydrogen,
    or its acid additive salts with antiarrhythmic activity.
    The purpose of the invention is to obtain new derivatives of 1,2,4-triazine, which have a different spectrum of biological properties in comparison with the known ones.
    The examples given illustrate the preparation of the proposed compounds and their use for the treatment of heart diseases.
    Example 1. Getting 3) -ami-6- (2,3-dichlorophenyl) -2,3 (2, j-di-hydro-3 (5) -imino-2-methyl-1,2,4-triazine .
    2,3-Dichlorobenzoic acid. A solution containing 37.3 g (0.1D M) of 2,3-dichloroiodobenzene in 300 ml of ether, dried with sodium, is added dropwise to magnesium chips in an amount of 3.65 g, and iodine crystals are added at heating, resulting in a Grignard reagent. The mixture thus obtained was stirred and heated at reflux for 2 hours, then cooled, transferred dropwise under a nitrogen atmosphere and introduced into a stirred mixture consisting of sodium-dried ether (250 ml) containing about 100 g of solid dioxide. carbon. The mixture thus obtained is stirred for 2 hours, then incubated for 12 hours, while the mixture is heated to room temperature. The mixture is then treated with ice (approximately 150 g) and then with a two-normal aqueous solution of hydrochloric acid (75 ml). A product obtained in such a manner is extra
    B
    etched in ether portions at 200, 100 and 50 ml. The mixed ether extracts are washed with water twice with 40 ml each, and then re-extracted.
    1G
    0
    25
    thirty
    A two-normal aqueous solution of sodium hydroxide is added in portions of 100, 50, and 50 ml. The resulting basic solutions were combined, mixed with activated carbon (3 g) for 10 minutes. The filter was filtered and the cooled filtrate was oxidized with concentrated hydrochloric acid (25 ml) at 10 ° C. The resulting solid product is filtered off, washed with water twice with 20 ml each time and dried in vacuo. The output of 20.76 g (77.6% of theoretical), so pl. 167-169 ° C (uncorrected).
    2,3-Dichlorobenzoyl chloride. A mixture of 39.4 g (0.2 M) of 2,3-dichlorobenzoic acid and 100 ml of thionyl chloride was heated under reflux for 2.5 hours. The resulting cooled solution was evaporated in vacuo, and then distilled under nitrogen. Output 35.5 g (85% of theoretical), so Kip. 146-148 ° C at a pressure of 31 mm Hg.
    2,3-Dichlorobenzoyl cyanide. A mixture of 36.9 g (0.41 mol) of monovalent copper cyanide, 68.5 g (0.41 mol) of potassium iodide and 400 ml of xylene is heated under reflux in a nitrogen atmosphere using a Dean trap. Starck for 24 hours to remove all traces of water from the mixture. A solution of 2,3-dichlorobenzoyl chloride (35.5 g of 0.17 M) in xylene, dried with sodium (130 ml), is added dropwise to this mixture consisting of anhydrous cyanide, monovalent copper and xylene. The mixture thus obtained was stirred and heated under reflux for a further 72 hours. The mixture was cooled and the cooled mixture was filtered. The resulting solid was thoroughly washed with xiol (200 ml), dried with sodium, the filtrate and the solution obtained after washing were combined and evaporated at B vacuum to give an oil. Yield 32 g (94% of theoretical).
    3,5-Diamino-6- (2,3-dichlorophenyl) -1, 2, 4 - triazine. A solution containing 32 g (0.16 M) of 2,3-dichlorobenzoyl cyanide in 80 ml of dimethyl sulfoxide, up to 36
    40
    45
    one
    Add dropwise a stirred suspension of aminoguanidine bicarbonate (81.67 g 0.6 M), which was previously treated with 8N. aqueous solution of nitric acid (400 ml) and at about 25 ° C. The mixture thus obtained is stirred for 3 hours and then kept at room temperature for 7 days. The cooled mixture was stirred and basified by adding 0.880 N, aqueous ammonia (400 ml) at and then stirred for 30 minutes while cooling with ice. The resulting solid was separated by filtration, washed thoroughly with water and dried in vacuo. Next, the solid product is added to a 10% (by volume) solution containing granules of potassium hydroxide in methanol in an amount of 400 ml and the resulting solution is heated under reflux for 1.5 hours. After cooling, the resulting solution is evaporated in vacuo - I, then treated with ice water (800 ml), stirred for 30 minutes and filtered. The residue obtained is dried and then recrystallized from isopropanol to obtain as a result of 3,5-diamino- (2,3-dichlorophenyl) 1,2,4-triazine. The output of 6.8 g (15.6% of theoretical), so pl.21b- 218 C.
    5 (3) -Amino-6- (2,3-dichlorophenyl) -2.3- (2,5) -dihydro-3- (5) -imino-2- -metnl-1,2,4-triazine .
    A mixture consisting of 2.56 g (10 mM) of 3,5-diamino-6- (2,3-dichlorophenyl) -1,2,4-triazine and 1.6 g (11 mM) of methyl iodide in 200 ml of acetone, stirred for 3 days at 21 ° C, and then evaporated in vacuo at 40 ° C to obtain a dry product. The resulting residue is treated with ice (about 50 g), and then 0,880 n. aqueous ammonia solution (100 ml). The product obtained is stirred for 30 minutes. The solid product is separated by filtration, dried in vacuo, and then subjected to recrystallization from methanol to give 5 (3) -amino-6- (2,3-dichlorophenyl) -2.3 (2,5) -dihydro-3 (5) -imin-2-methyl-1,2,4-triazine. Output 1.56 g (58% of theoretical), so pl. 228-230 s.
    Data analysis of the NMR spectrum (-dfi) 7,70 - 7,37 (ЗН, m. АНН) С 6.22
    500
    (ZN, sh.s. Sh) and 3.47 (ZN, p. NMe); H, Associated S.
    NMR (- d), 154.2 ppm (s.), 153.7 ppm (q), M / Z 269 (M) mass spectrum, 199 (C and 9J
    Me
    (
    Calculated,%: C 44.46, H 3.36, N 25.93.
    C ,, H ,,
    Found,%: C 44.61, H 3.25, N 25.63.
    Example 2. Getting 5 (3) -ami-6- (2,5-dichlorophenyl) -2,3 (2,5) -di-hydro-3 (5) -imino-2-methyl-1,2, 4-triazine.
    The hydroiodine salt of the title compound is prepared from 3,5-diamino-6- (2,6-dichlorophenyl) -1,2, -triazine according to the procedure described in example 1, and then the base is separated, as indicated in Example 1. This base is converted to the mesilate salt by treatment with methanesulfonic acid (1.2 ml) in methanol (100 ml). The resulting solution is evaporated in vacuo to give a dry product, the residue is recrystallized from methanol, and the resulting compound 5 (3) -amino-6- (2,5-dichlorophenyl) -2.3 (2.5) -dihydroxy 3 (5) -imino-2-methyl -1,2,4-tr azine. Output 0.93 g (35% of theoretical), so pl. 306-308 S.
    Example 3. Preparation of 5 (3) -amino-6- (2-norm-pentyloxyphenyl) -2,3- - (2,5-dihydro-3 (5) -imino-2-metn--1,2 , 4-triazine.
    Mesilate salt hemihydrate was prepared as described in Example 1. A yield of 1.76 g (46% of the theoretical), so pl. 192-195 S.
    PRI mme R 4. Get bnny 5 (3) -amino-6- (2,3-dichlorophenyl) -2,3 (2,5) -di-hydro-3 (5) -imino-2 -isopropyl-1,2,4-triazine.
    Suspension consisting of 3,5-diamino-6- (2,3-dichlorophenyl) -1,2,4-triazine (2.56 g, 10 mM) and isopropyl iodide (2 ml, 20 mM) in acetone (200 mM), stirred and boiled under reflux for 7 days. The suspension thus obtained is cooled and the solid precipitate formed is separated by filtration. In the processing of sediment 0,880 n. water
    ammonia solution, a base is obtained, which is converted to the monohydrate salt of meeilate in accordance with the method described in example 2. The resulting product is recrystallized from 95% ethanol. Yield 500 mg (12% of theoretical), t, mp, 251-252 C.
    Using techniques similar to those indicated in Examples 1-4, the following compounds were prepared.
    EXAMPLE 5. 5 (3-Amino-6- (2- -chloro-6-fluorophenyl) -2.3 (2.5) -dihydro-3- (5) -imino-2-methyl -1,2,4-triazine is obtained as the hydrochloride salt (0.3), mp 296-298 ° C.
    PRI me R 6. 5 (3) -Amino-6- (2- methoxyphenyl) -2,3 (2,5) -dihydro-3 (5) -imino-2-methyl-1,2 , 4-triazine is obtained in the form of a monohydrate salt of the mesylate, 213-216 ° C.
    Example. 5 (3) -Amino-6- (2,3-dichlorophenyl) -2,3 (2,5) -dihydro-3 (5) -imino-2-nor-propyl-1,2, A-tri- az in receive in the form of a salt of mesylate, t.pl. 265-266 ° C.
    PRI me R 8. 5 (3) -Amino-6- (2,4-dichlorophenyl) -2,3 (2,5) -dihydro-3 (5) - -imino-2-methyl-1 2,4-triazine is obtained in the form of a mesylate salt, i.e. 290-292 ° C.
    PRI me R 9. 5 (3) -Amino-6- (2,3- -dichlorophenyl) -2,3 (2,5) -dihydro-3 (5) - -imino-2-benzyl-1 , 2,4-triazine is obtained as a salt of the mesylate, mp 269-271 C.
    Example 10. 5 (H) -Amino-b- - (2,3,5-trichlorophenyl) -2,3 (2,5) -dihydro-3 (5) -imino-2-methyl-1,2, 4-triazine is obtained as the mesylate salt, m.p. 302-304 S.
    Example 11. 5 (3) -Amino-6- (4- -norm pentyloxyphenyl) 2,3 (2,5) -di-hydro-3 (5) -imino-2-methyl-1,2,4- the triazine is obtained as the mesylate salt, m.p. 195-200 ° C.
    Example 12. 5 (3) -Amino-6- (2-normpropylphenyl) -2.3 (2.5) -dihydro-3 (5) -imino-2-methyl-1,2,4 triazine is obtained in the form of a mesylate salt, m.p. 238-240 C.
    Example 13. 5 (3) -amino-6- (2-norm-propyloxyphenyl) -2.3 (2.5) -di-hydro-3 (5) -imino-2-methyl-1,2,4 triazine is obtained in the form of hydrochloride, so pl. 278-279 ° C.
    Example 14. 5 (3) -Amino-6- (2- -norm heptyloxyphenyl) -2.3 (2.5) -di715006
    hydro-3 (5) -imino-2-methyl-1,2,4-triazine receive in the form of hydrochloride, so pl. 247-249 0.
    5 Example 15. 5 (3) -Amino-6- (2,3- -dichlorophenyl) -2.3 (2.5) -dihydro-3 (5) - -imino-2-nor-pentyl-1,2 , 4-triazine is obtained in the form of a mesylate salt (0.66), so pl. 203-205 0. Since the determination, as was established, is unstable, the mesylate is obtained directly from the hydroiodide in an ion exchange column.
    P1 study of biological activity.
    A. Preparation of anesthetized rat.
    For conducting experiments used samdov Wistar rats (Wistar)
    20 weighing 200-300 g. Anesthesia of rats was elicited with halothane and air mixture and maintained by intravenous injection of a mixture consisting of chloroazole and sodium pentobarbitone (3 mg / ml
    25 pentobarbitol sodium and 9.5 mg / ml
    chlorazole), after entering the cannula in the femoral vein. The tracheal cannula was administered and the respiration of the animal was provided with a small respiratory
    30 palmer pump for animals
    (72 strokes / min, the volume of air supplied is about 1 ml / 100 g). During the entire experiment, the temperature was maintained at a temperature of 37 C.
    -jij were installed in the celiac vein to inject aconitine and in the carotid artery for continuous measurement of blood pressure. Subdermal needle electrodes were mounted on the body to record the electrocardiogram throughout the experiment.
    After the animal’s blood pressure was stabilized for 10–15 min, aconitin dissolved
    45 in distilled water + HC1 and diluted in 5% dextrose, was injected through the strap vein through the cannula at a rate of 1 mg / min (0.03 ml / min). A general dose of aconitin is required for
    50 in order to induce ventricular tachycardia or ventricular fibrillation (VT / VF) for at least 1 s, served as the final reference point when conducting this ext.
    gg periment.
    Antiarrhythmic activity was assessed using pretreated animals, which were randomly injected with either nepapar or carrier alone for 15 minutes on the administration of aconitine, and the dose of aconitine needed to cause ventricular arrhythmia in the treated group of animals was compared with the control a group of animals. The compounds according to the invention were administered in the form of a mesylate or a hydrochloride salt, prepared immediately before use, in the form of a 5% dextrose solution. All preparations were injected through cannula mounted on the femoral vein, the dose volume being 0.5 ml.
    Intravenous administration of aconitine to anesthetized rats quickly caused ventricular extrasystoles of both monofocal and multifocal origin. All animals died from rapid ventricular tachycardia or ventricular fibrillation. The dose needed to induce fast ventricular tachycardia (D 10 consecutive strokes) or ventricular fibrillation in control animals was 19.95j-0.6 (). Pretreatment of anesthetized rats with drugs such as procainamide, quinidine, phenytoin, propanolol, lidocaine, or verapamil increased the amount of aconitine required to cause exactly the same ventricular arrhythmia as in control animals (see table). Pretreatment with these standard antiarrhythmic agents also led to significant decreases in residual diastolic blood pressure (see table).
    Pretreatment of anesthesia to the rat using any proposed compound led to an increase, depending on the dose of the compound, on the amount of aconitine required to cause ventricular arrhythmia.
    The table shows the effect of some standard anti-arrhythmic agents and some compounds prepared in accordance with the invention to increase the dose of aconitine required to cause ventricular arrhythmia in anesthetized rats.
    B. Preparation of the right ventricular muscle of guinea pigs.
    five
    0
    five
    Strips of the right ventricular muscle muscle cut from male guinea pigs were subjected to electrical current stimulation at a frequency of 1 Hz using bipolar silver wire electrodes, poured with a modified Tykodes solution containing the compounds indicated in examples 1, 3 or 4 in the amount of 0-3x10 M. The effect of the compounds on the maximum rate of change of the membrane potential during the phase O of the active potential was observed ().
    Compounds in an amount of - 3x10 M caused a decrease in the rate of elevation of the O phase of the cardiac potential associated with the amount of the compound dose.
    The following is the EC value (50% reduction in V) for the compounds listed in Examples 1, 3 and 4.
    EU,
    0
    five
    0
    five
    0
    five
    yo
    M
    -four
    1.3x10 5.9x10 2.2x10
    Compound
    according to example 1 3 4
    B. Toxicity.
    When conducting experiments on dogs of the Goncha breed, no significant toxicity was found in those cases when the amount of the preparation exceeding 2-3 times the effective dose of the compound indicated in Example 4 was administered daily for 14 days. For rats, the acute lethal dose for the compound indicated in Example 4 was 8.34 ng / kg body weight when administered intravenously and 25.5 mg / kg body weight after subcutaneous injection.
    Pharmaceuticals.
    Tablet contains mg:
    5 (3) -amino-6- (2, .3-dichlorophenyl) -2,3 (2,5) -dihydro-3 (5) -amino-2-isopropyl-1, 2,4-triazine
    Lactose
    35.0 200
    Corn starch 50 Polyvinnippirrolidine 4 Magnesium stearate 3
    This preparation was mixed with lactose and starch and granulated with a solution of polyvinylpyrrolidine in water. The obtained granules were dried, mixed with magnesium stearate and tableted with 91
    radiation as a result of tablets having an average weight of 293 mg.
    2.Tablet contains mg: Compound characterized by the formula 1 35.0 Lactose 110.0 Wheat starch, subjected to preliminary gelation 2.5 Potato starch 12.0 Magnesium stearate 0.5 Active compound was subjected
    finely ground, and then thoroughly mixed with powdered fillers - lactose, wheat starch and magnesium stearate. From the resulting mixture, tablets weighing 160 mg each were obtained by tabulating.
    3. Injections contain: A compound characterized by the formula 35.0 mg. Water for injection, up to the required amount of 1.0 ml. The finely divided active compound was dissolved in the water used for injection. The resulting solution was filtered and sterilized in an autoclave.
    4. Candle contains: Compound characterized by formula I 35.0 mg Cocoa butter2.0 g
    or Wecobee is the basis for the required amount, Wecobee is the trade name of the hydrogenated fatty carboxylic acid.
    The fine active compound was mixed with a melted candle base (either cocoa butter or Wecobee® candle base, this mixture was poured into molds and cooled to result in the required suppositories (candles).
    5. Syrup contains, mg per 5 ml: Compound characterized by the formula I35.0 Ethanol 0.3 Sucrose2.0 Methylparaben 0.5 Sodium benzoate 0.5 Cherry syrup Until needed
    Amount of Dye Till Necessary
    Quantity Water in the required amount Up to 5.0 ml
    500
    ten
    Ethanol, sucrose, sodium benzoate, methylparaben and flavoring substance (cherry syrup) were mixed in 70% of the total amount of water required. The dye and active compound were dissolved in the remaining water, then the two solutions were mixed and clarified by filtration.
    6. Capsule contains mg: Compound characterized by formula I 35.0 Lactose440.0
    Magnesium Stearate 5.0
    权利要求:
    Claims (1)
    [1]
    1. A method for producing triazine derivatives of the general formula
    where is r,
    N -N-R,
    g
    - C, -C-alkyl, unsubstituted or substituted by phenyl,
    R 2 is Rg- independently two or three halo groups, or any of R, R4 means. -Alkyl or C, sigroup, and in any case, the remaining RI-RJ-BO-pred,
    or its acid addition salts, characterized in that the compound of the general formula
    tl R
    RS N-H
     D; -Mi H2N N
    where R Re has the indicated meanings, is reacted with a compound of the general formula
    1 - Q /
    where R has the indicated meanings
    O - halogen,
    followed by isolation of the desired product in the free state or in the form of an acid addition salt.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1371500A3|1988-01-30|Method of producing triazine or acid-additive salts thereof
    DD151309A5|1981-10-14|METHOD FOR THE PRODUCTION OF SUBSTITUTED AMINOTRIAZINES
    EP0247892B1|1991-04-24|Triazine salt
    SU1402259A3|1988-06-07|Method of producing substituted 2-phenylhexahydro-1,2,4-triazine-3,5-diones
    US3140231A|1964-07-07|T-octylguanidines as antihypertensive agents
    DE2527065A1|1976-01-08|5-PROPYLTHIO-2-BENZIMIDAZOLE CARBAMIC ACID METHYLESTER
    CS195280B2|1980-01-31|Method of producing substituted chalcones
    IL30782A|1972-08-30|Amino guanidines
    JP2865255B2|1999-03-08|1,2,3,4,10,14b-Hexahydrodibenzo [c, f] pyrazino [1,2-a] azepino derivatives and 10-aza, 10-oxa and 10-thia analogs
    US3769432A|1973-10-30|Compositions and method of use of substituted guanidines
    FI62089B|1982-07-30|FREQUENCY REQUIREMENT FOR THE PERFORMANCE OF PERIPHERAL BLODOMLOPPET NETWORK 7- | -N-AMINO) -1,3-DIALKYL-XANTINDERIVAT
    FI57942C|1980-11-10|FOERFARANDE FOER FRAMSTAELLNING AV NYA 2-PHENYLHYDRAZINOTIAZOLINER ELLER -TIAZINER FOER ANVAENDNING SAOSOM HYPNOTIC ELLER NARCOTIC MEDICINE
    US3682912A|1972-08-08|Di-hydro triazine derivatives
    CH642668A5|1984-04-30|2,6-DIAMINONEBULARINE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME.
    US4374136A|1983-02-15|Pyrimidine derivatives
    CA1250576A|1989-02-28|Quinazolin-4-one-3-acetonyl hydrazone and their useagainst coccidiosis
    DE1965711B2|1978-07-13|l ^ -Dihydro-133-triazine derivatives, processes for their preparation and medicaments containing them
    US3634446A|1972-01-11|1-methyl-2-isopropyl-5-nitroimidazole and water soluble salts thereof
    US3076805A|1963-02-05|New 1-| alkyl)-3-|-2-imidazolidinethiones
    KR890001151B1|1989-04-25|Preparation method of imidazole carboxylic acid derivatives
    US4151298A|1979-04-24|Anthelmintic compositions
    GB2086386A|1982-05-12|Pyrimidine derivatives
    US4073791A|1978-02-14|1-Substitutedphenyl-4|-pyridinone hydrazones
    US3773943A|1973-11-20|Alpha,alpha,alpha-trifluoro-6-substituted-5-nitro-m-toluic acid,5'-nitrofurylidene hydrazide compounds as growth promotants
    DE2008693A1|1970-09-24|New 'pyrazolines
    同族专利:
    公开号 | 公开日
    JPS60109577A|1985-06-15|
    ES8606304A1|1986-04-16|
    AU564667B2|1987-08-20|
    PL144899B1|1988-07-30|
    DK512184D0|1984-10-26|
    EP0142306A2|1985-05-22|
    GB8328757D0|1983-11-30|
    KR850002964A|1985-05-28|
    MC1628A1|1985-09-26|
    KR890000991B1|1989-04-15|
    ES537104A0|1986-04-16|
    IL73332D0|1985-01-31|
    EP0142306A3|1986-11-20|
    CA1261328A|1989-09-26|
    PL250213A1|1985-12-03|
    PT79416A|1984-11-01|
    DK512184A|1985-04-28|
    AU3475884A|1985-05-09|
    US4649139A|1987-03-10|
    NZ210000A|1987-08-31|
    HU191566B|1987-03-30|
    PH21926A|1988-04-08|
    FI844212A0|1984-10-26|
    GR80723B|1985-02-07|
    ZA848388B|1986-06-25|
    DD224033A5|1985-06-26|
    FI844212L|1985-04-28|
    HUT36102A|1985-08-28|
    PT79416B|1986-11-13|
    IL73332A|1988-06-30|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB759014A|1952-02-26|1956-10-10|Wellcome Found|Improvements in triazines and their manufacture|
    DE1770750C3|1968-06-29|1980-01-31|Bayer Ag, 5090 Leverkusen|5-Imino-l ^, 4-triazine derivatives, process for their preparation and their use for combating weeds|
    US3637688A|1970-01-09|1972-01-25|American Home Prod|6--3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines|
    DE2003144C3|1970-01-24|1980-01-10|Bayer Ag, 5090 Leverkusen|5-Imino-6-alkyl-1 ^ 2,4-triazine derivatives and processes for their preparation|
    EP0021120B1|1979-06-01|1983-04-06|The Wellcome Foundation Limited|3,5-diamino-1,2,4-triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them|
    DD151309A5|1979-06-01|1981-10-14|Wellcome Found|METHOD FOR THE PRODUCTION OF SUBSTITUTED AMINOTRIAZINES|
    US4616014A|1981-10-22|1986-10-07|Fujisawa Pharmaceutical Co., Ltd.|Triazine derivatives, and pharmaceutical compositions comprising the same|GB8613183D0|1986-05-30|1986-07-02|Wellcome Found|Triazine salt|
    GB9012312D0|1990-06-01|1990-07-18|Wellcome Found|Pharmacologically active cns compounds|
    GB9218113D0|1992-08-26|1992-10-14|Lilly Industries Ltd|Pharmaceutical compounds|
    GB9726987D0|1997-12-22|1998-02-18|Glaxo Group Ltd|Compounds|
    DE10085384B4|2000-01-03|2006-06-14|Rpg Life Sciences Limited|Preparation of 6--1,2,4-triazine-3,5-diamine , useful for treating epilepsy, starting from 2,3-dichloronitrobenzene|
    IL134730A|2000-02-25|2003-10-31|Chemagis Ltd|Process for preparing substituted benzoyl cyanide amidinohydrazones|
    AU2002322720B2|2001-07-25|2008-11-13|Raptor Pharmaceutical Inc.|Compositions and methods for modulating blood-brain barrier transport|
    JP2008539047A|2005-04-28|2008-11-13|プロテウスバイオメディカルインコーポレイテッド|Pharma Informatics System|
    WO2008036682A2|2006-09-18|2008-03-27|Raptor Pharmaceutical Inc.|Treatment of liver disorders by administration of receptor-associated protein -conjugates|
    GB0613836D0|2006-07-13|2006-08-23|Univ Greenwich|New medical use of triazine derivatives|
    GB0800741D0|2008-01-16|2008-02-20|Univ Greenwich|Cyclic triazo and diazo sodium channel blockers|
    CN104208718B|2009-02-20|2017-12-29|2-Bbb医疗股份有限公司|drug delivery system based on glutathione|
    GB2471713A|2009-07-08|2011-01-12|Univ Greenwich|1,2,4-triazine derivatives and their use as sodium channel blockers|
    GB2471729A|2009-07-08|2011-01-12|Univ Greenwich|1,2,4-triazine derivatives and their use as sodium channel blockers|
    US20120077778A1|2010-09-29|2012-03-29|Andrea Bourdelais|Ladder-Frame Polyether Conjugates|
    CN107921046A|2015-06-12|2018-04-17|格林威治大学|Pyrrolotriazine derivatives as interferon Γ inhibitor|
    GB202006076D0|2020-04-24|2020-06-10|Univ Greenwich|Interleukin inhibitors|
    GB202006080D0|2020-04-24|2020-06-10|Univ Greenwich|Cytokine storm syndrome|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB838328757A|GB8328757D0|1983-10-27|1983-10-27|Chemical compounds|
    [返回顶部]